NovoCure (NVCR) Competitors $17.75 -0.45 (-2.47%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$17.71 -0.04 (-0.23%) As of 05/21/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NVCR vs. STVN, GKOS, NARI, INSP, IRTC, BLCO, TMDX, SLNO, NVST, and PRCTShould you be buying NovoCure stock or one of its competitors? The main competitors of NovoCure include Stevanato Group (STVN), Glaukos (GKOS), Inari Medical (NARI), Inspire Medical Systems (INSP), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Envista (NVST), and PROCEPT BioRobotics (PRCT). These companies are all part of the "medical equipment" industry. NovoCure vs. Stevanato Group Glaukos Inari Medical Inspire Medical Systems iRhythm Technologies Bausch + Lomb TransMedics Group Soleno Therapeutics Envista PROCEPT BioRobotics NovoCure (NASDAQ:NVCR) and Stevanato Group (NYSE:STVN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, earnings, community ranking, media sentiment, risk, dividends and valuation. Does the media refer more to NVCR or STVN? In the previous week, NovoCure and NovoCure both had 7 articles in the media. NovoCure's average media sentiment score of 1.49 beat Stevanato Group's score of 1.44 indicating that NovoCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NovoCure 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stevanato Group 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is NVCR or STVN more profitable? Stevanato Group has a net margin of 10.47% compared to NovoCure's net margin of -25.93%. Stevanato Group's return on equity of 9.86% beat NovoCure's return on equity.Company Net Margins Return on Equity Return on Assets NovoCure-25.93% -41.48% -12.74% Stevanato Group 10.47%9.86%5.79% Which has more risk & volatility, NVCR or STVN? NovoCure has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500. Comparatively, Stevanato Group has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Does the MarketBeat Community favor NVCR or STVN? NovoCure received 447 more outperform votes than Stevanato Group when rated by MarketBeat users. However, 63.27% of users gave Stevanato Group an outperform vote while only 62.98% of users gave NovoCure an outperform vote. CompanyUnderperformOutperformNovoCureOutperform Votes47862.98% Underperform Votes28137.02% Stevanato GroupOutperform Votes3163.27% Underperform Votes1836.73% Which has preferable valuation and earnings, NVCR or STVN? Stevanato Group has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNovoCure$621.71M3.18-$207.04M-$1.51-11.75Stevanato Group$1.12B6.46$157.62M$0.5147.06 Do insiders & institutionals have more ownership in NVCR or STVN? 84.6% of NovoCure shares are owned by institutional investors. 6.3% of NovoCure shares are owned by company insiders. Comparatively, 0.7% of Stevanato Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Do analysts recommend NVCR or STVN? NovoCure currently has a consensus target price of $32.83, indicating a potential upside of 84.98%. Given NovoCure's higher probable upside, equities analysts plainly believe NovoCure is more favorable than Stevanato Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NovoCure 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86 SummaryStevanato Group beats NovoCure on 11 of the 17 factors compared between the two stocks. Get NovoCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NVCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVCR vs. The Competition Export to ExcelMetricNovoCureSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.98B$4.50B$5.38B$8.39BDividend YieldN/A43.63%5.21%4.10%P/E Ratio-12.6829.4326.8019.71Price / Sales3.1867.72389.70117.54Price / CashN/A51.0838.2534.62Price / Book5.246.236.804.50Net Income-$207.04M$68.16M$3.23B$248.18M7 Day Performance0.91%-0.19%1.52%0.23%1 Month Performance7.51%19.19%10.04%12.39%1 Year Performance-25.11%21.47%16.73%7.07% NovoCure Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVCRNovoCure3.6348 of 5 stars$17.75-2.5%$32.83+85.0%-22.0%$1.98B$621.71M-12.681,320Positive NewsSTVNStevanato Group1.2945 of 5 stars€23.60-1.7%N/A+24.6%$7.15B$1.10B50.214,650Positive NewsGKOSGlaukos4.6187 of 5 stars$94.57+5.1%$134.67+42.4%-12.5%$5.40B$404.52M-32.95780Positive NewsNARIInari Medical0.5692 of 5 stars$79.97flat$69.22-13.4%N/A$4.68B$493.63M-59.24800INSPInspire Medical Systems4.675 of 5 stars$156.54+3.5%$211.91+35.4%-4.0%$4.62B$840.11M90.49760Positive NewsGap UpIRTCiRhythm Technologies1.2741 of 5 stars$137.88+0.1%$128.55-6.8%+52.9%$4.40B$618.59M-37.881,790Positive NewsBLCOBausch + Lomb4.1449 of 5 stars$11.91+5.6%$15.50+30.2%-22.8%$4.21B$4.83B-13.0812,500Gap UpTMDXTransMedics Group1.3197 of 5 stars$118.75+6.5%$126.70+6.7%-12.4%$4.02B$488.23M126.33210Positive NewsSLNOSoleno Therapeutics4.8537 of 5 stars$76.58-0.3%$106.78+39.4%+65.6%$3.86BN/A-23.0730News CoveragePositive NewsNVSTEnvista4.1759 of 5 stars$18.56+5.5%$20.08+8.2%-9.2%$3.15B$2.50B-2.8612,700Positive NewsGap UpPRCTPROCEPT BioRobotics2.923 of 5 stars$54.40+2.4%$90.00+65.4%-17.6%$3.01B$249.12M-27.90430Positive NewsGap Up Related Companies and Tools Related Companies Stevanato Group Alternatives Glaukos Alternatives Inari Medical Alternatives Inspire Medical Systems Alternatives iRhythm Technologies Alternatives Bausch + Lomb Alternatives TransMedics Group Alternatives Soleno Therapeutics Alternatives Envista Alternatives PROCEPT BioRobotics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVCR) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovoCure Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share NovoCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
